Co-administration of an adjuvanted FeLV vaccine together with a multivalent feline vaccine to cats is protective against virulent challenge with feline leukaemia virus, calicivirus, herpes virus and panleukopenia virus

Wilson, Stephen E.; Saunders, Gillian; Stoeva, Mira I.; Ludlow, Deborah; Reitzenstein, M.; Sture, Gordon; Salt, Jeremy; Thompson, James P.

doi:10.1016/j.trivac.2013.12.002

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously demonstrated that the co-administration of the combination vaccine described herein, together with a new feline leukaemia vaccine also has no negative impact on either vaccine's efficacy [17]. Although there was no challenge with virulent viruses in this current series of studies, the antibody titres achieved following vaccination were equivalent to those obtained in separate challenge efficacy studies with herpesvirus, calicivirus and panleucopaenia virus in which vaccinated cats were protected; showing reductions in clinical signs, virus excretion and leucopaenia.…”

Section: Discussionmentioning

confidence: 90%

The efficacy of a multivalent calicivirus, herpesvirus and parvovirus vaccine and a rabies vaccine is not affected when administered in combination

Wilson

King

Sture

2015

Trials in Vaccinology

Self Cite

View full text Add to dashboard Cite

a b s t r a c tThe results of a serological study examining the antibody responses generated in cats following administration of a trivalent feline vaccine (feline calicivirus [FCV], feline herpesvirus [FHV] and feline panleucopaenia virus [FPV]; Versifel CVR) in combination with an inactivated rabies vaccine, in compliance with European Pharmacopoeia requirements to support new product registrations, are presented.Nine week old cats were allocated to one of three groups, 10 cats per group. Group 1 received the CVR vaccine on days 0 and 21, group 2 received the rabies vaccine on day 21 and group 3 received the CVR vaccine on day 0 and the CVR vaccine reconstituted with the rabies vaccine (i.e., administered simultaneously) on day 21. Blood samples were collected from each animal, on days 0, 21, 28, 35, 42 and 49; and antibody titres determined using haemagglutination inhibition assay or virus neutralisation test.FHV and FPV antibody responses in the group 3 combination administration were considered non -inferior to the responses in the group 1 CVR-only at all time points (days 28, 35, 42 and 49). However for FCV, group 3 was considered non-inferior to the responses in group 1 on days 28, 35 and 42; but not on day 49. For rabies, group 3 was only considered non-inferior to the responses in group 2 on day 49; an apparent inferiority was observed on days 28, 35 and 42. However, in all cases cats that received the combination administration seroconverted with antibody titres at a magnitude shown in other studies to be protective against virulent challenge, and also at a titre deemed adequate by the European Pharmacopeia monograph 04/2013:0451 (Rabies vaccine [inactivated] for Veterinary use).In conclusion, the data show that combining these two separate vaccines in one administration has limited impact on their ability to generate serological responses, and that these responses are still of a magnitude previously demonstrated to be protective.

show abstract

Section: Discussionmentioning

confidence: 90%

The efficacy of a multivalent calicivirus, herpesvirus and parvovirus vaccine and a rabies vaccine is not affected when administered in combination

Wilson

King

Sture

2015

Trials in Vaccinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The efficacies of FeLV vaccines other than the Fel-O-Vax ® range, administered as either monovalent or polyvalent formulations, have been shown to be comparable. For example, in a study to determine the efficacy of Versifel ® FeLV (Zoetis Animal Health; an IWV vaccine containing FeLV-A, FeLV-B and FeLV-C), administered at the same time as a modified live-virus (MLV) trivalent core vaccine, no difference in FeLV vaccine efficacy was observed when the two vaccines were given concurrently (the FeLV component was injected subcutaneously at the base of the neck and the MLV component was injected subcutaneously in the left thoracic wall) compared to simultaneous administration (the MLV component was reconstituted using the FeLV vaccine and the entire contents were administered subcutaneously at the base of the neck) [ 57 ]. Similarly, in a study investigating the efficacy of a canarypox virus-vectored FeLV vaccine (Purevax ® FeLV, Merial), no difference in vaccine efficacy was observed, whether the FeLV component was administered as a monovalent or polyvalent vaccine [ 58 ].…”

Section: Discussionmentioning

confidence: 99%

Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax® Lv-K and Fel-O-Vax® 5)

Westman

Norris

Malík

et al. 2021

Viruses

View full text Add to dashboard Cite

A field study undertaken in Australia compared the antibody responses induced in client-owned cats that had been vaccinated using two inactivated whole feline leukaemia virus (FeLV) vaccines, the monovalent vaccine Fel-O-Vax® Lv-K and the polyvalent vaccine Fel-O-Vax® 5. Serum samples from 428 FeLV-uninfected cats (118 FeLV-vaccinated and 310 FeLV-unvaccinated) were tested for anti-FeLV neutralising antibodies (NAb) using a live virus neutralisation assay to identify 378 FeLV-unexposed (NAb-negative) and 50 FeLV-exposed (NAb-positive; abortive infections) cats, following by anti-surface unit (SU) FeLV-A and FeLV-B antibody ELISA testing. An additional 42 FeLV-infected cats (28 presumptively regressively infected, 14 presumptively progressively infected) were also tested for anti-SU antibodies. NAb-positive cats displayed significantly higher anti-SU antibody ELISA responses compared to NAb-negative cats (p < 0.001). FeLV-unexposed cats (NAb-negative) that had been vaccinated less than 18 months after a previous FeLV vaccination using the monovalent vaccine (Fel-O-Vax® Lv-K) displayed higher anti-SU antibody ELISA responses than a comparable group vaccinated with the polyvalent vaccine (Fel-O-Vax® 5) (p < 0.001 for both anti-FeLV-A and FeLV-B SU antibody responses). This difference in anti-SU antibody responses between cats vaccinated with the monovalent or polyvalent vaccine, however, was not observed in cats that had been naturally exposed to FeLV (NAb-positive) (p = 0.33). It was postulated that vaccination with Fel-O-Vax® 5 primed the humoral response prior to FeLV exposure, such that antibody production increased when the animal was challenged, while vaccination with Fel-O-Vax® Lv-K induced an immediate preparatory antibody response that did not quantitatively increase after FeLV exposure. These results raise questions about the comparable vaccine efficacy of the different FeLV vaccine formulations and correlates of protection.

show abstract

Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study

Blake,

Thompson,

HogenEsch

et al. 2024

Vaccine

View full text Add to dashboard Cite

Co-administration of an adjuvanted FeLV vaccine together with a multivalent feline vaccine to cats is protective against virulent challenge with feline leukaemia virus, calicivirus, herpes virus and panleukopenia virus

Cited by 3 publications

References 24 publications

The efficacy of a multivalent calicivirus, herpesvirus and parvovirus vaccine and a rabies vaccine is not affected when administered in combination

The efficacy of a multivalent calicivirus, herpesvirus and parvovirus vaccine and a rabies vaccine is not affected when administered in combination

Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax® Lv-K and Fel-O-Vax® 5)

Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study

Contact Info

Product

Resources

About